Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
StockStory.org on MSN2h
Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated TodayShares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 27.6% in the afternoon session after the company delivered mixed fourth-quarter 2024 results: It added fewer customers than expected, ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...
Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular ...
Hims & Hers Health (HIMS) stock crashes even as the company reported better than expected Q4 2024 results and issued a bullish outlook. Read more here.
It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...
Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, Home ...
Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback